Ads
related to: mayo clinic aml leukemia life expectancy adults over 50- Clinical Recommendations
Info On a Treatment Recommendation
From An AML Treatment Guideline.
- AML Treatment Option
See If an AML Treatment Option
May Be Able To Help Your Patients.
- Testing For AML
Learn About The Importance of
Testing For Mutations in AML.
- View Dosing Guidelines
Clinical Dosing Guidelines For
an AML Treatment Option.
- View The Clinical Data
Explore The Clinical Data
For an AML Treatment Option.
- Safety & Efficacy Info
View The Potential Adverse
Reactions For a Treatment Option.
- Clinical Recommendations
Search results
Results From The WOW.Com Content Network
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. [1] Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. [1]
Acute monocytic leukemia (AMoL, or AML-M5) [2] is a type of acute myeloid leukemia. In AML-M5 >80% of the leukemic cells are of monocytic lineage. [3] This cancer is characterized by a dominance of monocytes in the bone marrow. There is an overproduction of monocytes that the body does not need in the periphery.
The underlying pathophysiology of acute myeloid leukemia consist of maturational arrest of the bone marrow cell during the early stages of development. A myeloblast is an immature precursor cell that will change into a monocyte, healthy white blood cell. In AML, Myeloblast do not mature but grow and multiply with regulation.
Acute leukemia or acute leukaemia is a family of serious medical conditions relating to an original diagnosis of leukemia. In most cases, these can be classified according to the lineage, myeloid or lymphoid , of the malignant cells that grow uncontrolled, but some are mixed and for those such an assignment is not possible.
Acute lymphoblastic leukemia represents approximately 20% of adults and 80% of childhood leukemias, making it the most common childhood cancer. [5] Although 80 to 90% of children will have a long term complete response with treatment, [ 45 ] : 1527 it remains the leading cause of cancer-related deaths among children.
This example uses the Acute Myelogenous Leukemia survival data set "aml" from the "survival" package in R. The data set is from Miller (1997) [1] and the question is whether the standard course of chemotherapy should be extended ('maintained') for additional cycles. The aml data set sorted by survival time is shown in the box.
Ads
related to: mayo clinic aml leukemia life expectancy adults over 50